Tivic Health Systems (TIVC) investor relations material

Company overview and business model

• Transitioned from a bioelectronic medical device company to a focused biopharmaceutical firm centered on TLR5 agonist programs, primarily Entolimod and its next-generation compound Entolasta.

• Entolimod targets Acute Radiation Syndrome (ARS) and oncology-related indications such as neutropenia, with Fast Track and Orphan Drug designations from the FDA.

• Established Velocity Bioworks, a wholly owned CDMO subsidiary, to support internal manufacturing and offer services to third parties.

• Exited consumer healthtech and non-invasive cervical vagus nerve stimulation businesses to focus resources on biologics.

Financial performance and metrics

• Incurred approximately $347,000 in charges in 2025 related to the wind-down of the consumer business, with an additional $20,000–$50,000 expected to complete the process.

• Minimal revenue expected during the transition period as the company pivots to its new business model.

Use of proceeds and capital allocation

• Proceeds from the sale of shares to Tumim Stone Capital, if any, will be used for general corporate purposes, including operating expenses, capital expenditures, and working capital.

• Management retains broad discretion over the allocation of any net proceeds received.